CRIS Current Research Information System

PALLESCHI, MICHELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.882
NA - Nord America 1.487
EU - Europa 809
SA - Sud America 132
Continente sconosciuto - Info sul continente non disponibili 123
AF - Africa 56
OC - Oceania 3
Totale 5.492
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.419
VN - Vietnam 1.059
SG - Singapore 671
CN - Cina 588
IT - Italia 306
HK - Hong Kong 207
NL - Olanda 138
KR - Corea 107
BR - Brasile 103
BD - Bangladesh 90
DE - Germania 78
FR - Francia 61
SE - Svezia 56
FI - Finlandia 54
JP - Giappone 43
IN - India 40
CI - Costa d'Avorio 29
CA - Canada 24
GB - Regno Unito 20
IE - Irlanda 20
ID - Indonesia 18
MX - Messico 16
PH - Filippine 15
RU - Federazione Russa 15
AT - Austria 13
TH - Thailandia 12
SC - Seychelles 11
PL - Polonia 10
AR - Argentina 9
CH - Svizzera 9
CR - Costa Rica 8
EC - Ecuador 8
JO - Giordania 7
BE - Belgio 6
BG - Bulgaria 6
IQ - Iraq 6
CO - Colombia 4
CZ - Repubblica Ceca 4
ES - Italia 4
JM - Giamaica 4
MA - Marocco 4
TW - Taiwan 4
BO - Bolivia 3
EG - Egitto 3
GH - Ghana 3
HN - Honduras 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BS - Bahamas 2
DO - Repubblica Dominicana 2
LT - Lituania 2
OM - Oman 2
PK - Pakistan 2
SA - Arabia Saudita 2
SV - El Salvador 2
TG - Togo 2
TT - Trinidad e Tobago 2
UA - Ucraina 2
UZ - Uzbekistan 2
VE - Venezuela 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
CG - Congo 1
CL - Cile 1
ET - Etiopia 1
IL - Israele 1
KN - Saint Kitts e Nevis 1
LB - Libano 1
LC - Santa Lucia 1
LV - Lettonia 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
SI - Slovenia 1
TR - Turchia 1
UY - Uruguay 1
VC - Saint Vincent e Grenadine 1
XK - ???statistics.table.value.countryCode.XK??? 1
YE - Yemen 1
ZA - Sudafrica 1
Totale 5.370
Salva come PNG Salva come JPEG
Città #
Singapore 506
Ho Chi Minh City 306
Hanoi 272
Hefei 249
San Jose 225
Hong Kong 194
Ashburn 166
Santa Clara 123
Seoul 101
Amsterdam 94
Dallas 85
Council Bluffs 79
Bologna 75
Los Angeles 51
Beijing 50
Boardman 39
New York 38
Tokyo 37
Helsinki 36
Da Nang 35
Lauterbourg 33
Haiphong 30
Abidjan 29
Bengaluru 25
Buffalo 25
Ha Long 23
Milan 22
Chandler 20
Dublin 20
Quận Bình Thạnh 20
Thái Nguyên 19
São Paulo 17
Nuremberg 16
Biên Hòa 15
Can Tho 15
Frankfurt am Main 15
Munich 15
Jakarta 14
Chicago 13
Hải Dương 13
Rome 13
Lappeenranta 12
Mexico City 11
Phủ Lý 11
Bắc Giang 10
Falkenstein 10
Ninh Bình 10
Princeton 10
Bắc Ninh 9
Düsseldorf 9
Redondo Beach 9
Vienna 9
Vinh 9
Vũng Tàu 9
Guangzhou 8
Montreal 8
Xi'an 8
Amman 7
Florence 7
Monzuno 7
Quận Một 7
Quận Phú Nhuận 7
Quận Sáu 7
Rio de Janeiro 7
San Francisco 7
Shanghai 7
Wilmington 7
Atlanta 6
Brooklyn 6
Cesena 6
Quận Bảy 6
Salt Lake City 6
San José 6
Sofia 6
Southend 6
Turin 6
Turku 6
Warsaw 6
Bern 5
Brussels 5
Casalecchio di Reno 5
Changsha 5
Hangzhou 5
Lấp Vò 5
Modena 5
Nam Định 5
Qingdao 5
Quận Tân Phú 5
Rimini 5
Thái Bình 5
Toronto 5
Bạc Liêu 4
Can Giuoc 4
Chengdu 4
Denver 4
Fuzhou 4
Houston 4
Huế 4
London 4
Orem 4
Totale 3.562
Salva come PNG Salva come JPEG
Nome #
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 358
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 353
HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer 321
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer 187
Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity 186
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 185
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy 181
Eribulin in brain metastases of breast cancer: Outcomes of the EBRAIM prospective observational trial 178
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis 165
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 157
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure 156
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 149
Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient 143
Case Report: Analysis of Plasma Extracellular Vesicles in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient 133
Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond 129
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment 128
Moving beyond parp inhibition: Current state and future perspectives in breast cancer 126
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 122
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 121
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 115
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial. 113
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report 111
ANTIANGIOGENIC AGENTS ARE INEFFECTIVE TO INCREASE COMPLETE RESPONSE RATE IN MRCC. A META-ANALYSIS 102
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 94
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 94
Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives 88
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer 87
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 86
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 84
Are we ready to use TMB in breast cancer clinical practice? 81
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 77
Atezolizumab plus Nab-paclitaxel in PD-L1–Positive TNBC—Letter 69
Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions 65
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? 61
ROLE OF HPV VACCINATION AFTER CARCINOMA IN SITU OF CERVIX UTERI (CIN) IN REAL-WORLD PATIENTS 60
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 59
Survey on cancer patients’ attitudes towards AI and data protection: A cross-sectional study from an Italian cancer center 57
Hormonal Therapy For Endometriosis And The Risk Of Endometriosis-Associated Gynecologic Cancers: A Propensity Score-Adjusted Real-World Data Study 52
Germline BRCA-mutated metastatic breast cancer with positive hormone receptor 51
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 47
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study 45
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough? 44
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report 36
Corrigendum to “Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives” [Crit. Rev. Oncol./Hematol. 181 (2023) 103900] (Critical Reviews in Oncology / Hematology (2023) 181, (S1040842822003249), (10.1016/j.critrevonc.2022.103900)) 35
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET 34
Precision medicine: PI3K targeting in advanced breast cancer 27
Ribociclib and endocrine therapy in breast cancer 24
Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients 18
Multiparametric whole-body magnetic resonance imaging in breast cancer management: A prospective study 18
The promise of liquid biopsy in cancer: A clinical perspective 18
Artificial intelligence for predicting pathological complete response to neoadjuvant therapy in triple-negative breast cancer: A systematic review and meta-analysis 17
Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer 17
Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching 17
Corrigendum to “Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching”(European Journal of Cancer, (2026), 242, C, (116818), (S095980492600599X), 10.1016/j.ejca.2026.116818) 9
Elucidating PI3K/AKT/PTEN Pathway Alterations at Single-Cell Level in CTCs From HR+/HER2− Metastatic Breast Cancer 2
Totale 5.492
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.249
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.249
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202257 0 0 0 4 4 0 3 2 0 9 24 11
2022/2023128 5 11 5 16 7 13 2 8 33 4 9 15
2023/2024143 1 6 1 5 2 7 9 6 66 17 11 12
2024/2025976 35 119 77 68 156 58 40 31 7 89 73 223
2025/20263.894 712 453 424 281 253 69 348 157 535 217 167 278
2026/2027294 118 176 0 0 0 0 0 0 0 0 0 0
Totale 5.492